Response Genetics (Response Genetics) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2015)

View and export this data going back to 2007. Start your Free Trial

What is Response Genetics 3-Year EBITDA Growth Rate?

Response Genetics's EBITDA per Share for the three months ended in Mar. 2015 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of Response Genetics's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Response Genetics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Response Genetics's 3-Year EBITDA Growth Rate falls into.

Response Genetics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Response Genetics (OTCPK:RGDXQ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Response Genetics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Response Genetics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Genetics (Response Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070

Website

http://www.responsegenetics.com

Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.

Executives

Roberto Mignone	10 percent owner	C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber	director	15 TROTTERS LANE, MONROE CT 06468
Sam Chawla	director	1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris	officer: Vice President and CFO	345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya	director	C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna	director, officer: Chief Executive Officer	4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-22-2009

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor • 12-14-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009